Grants per year
Search results
-
Finished
Prot#TAK-018-2001: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Bellaguarda, E. A. L. (PD/PI)
Pharmaceutical Research Associates, Inc., Millennium Pharmaceuticals, Inc.
12/17/21 → 12/17/24
Project: Research project
-
Prot# Cx601-0303: A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex
Bellaguarda, E. A. L. (PD/PI) & Hanauer, S. B. (Other)
7/30/21 → 7/30/24
Project: Research project
-
Validation of a Machine Learning Algorithm to Assess Colonoscopic Disease Activity in Inflammatory Bowel Disease
Bellaguarda, E. A. L. (PD/PI) & Keswani, R. N. (PD/PI)
Virgo Surgical Video Solutions, Inc
6/15/21 → 10/31/22
Project: Research project
-
Prot#M14-533: A Phase 3 multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of ABT-494 in subjects with ulcerative colitis (UC)
Bellaguarda, E. A. L. (PD/PI)
7/29/20 → 7/29/23
Project: Research project
-
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes
Bellaguarda, E. A. L. (PD/PI), Bass, M. (Co-Investigator) & Hanauer, S. B. (Co-Investigator)
Icahn School of Medicine at Mount Sinai, National Center for Advancing Translational Sciences
4/20/20 → 6/30/23
Project: Research project
-
Protocol M14-234: A Multicenter, Randomized, Double-Blind, Placebo -Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI) & Hanauer, S. B. (PD/PI)
7/23/19 → 7/23/22
Project: Research project
-
Protocol M16-000: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006
Bellaguarda, E. A. L. (PD/PI)
7/1/19 → 3/4/23
Project: Research project
-
Protocol M15-991: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who failed Prior Biologic Treatment (Abbvie M15-
Bellaguarda, E. A. L. (PD/PI)
6/14/19 → 6/14/22
Project: Research project
-
Vedolizumab-4014: A Phase 4, Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI)
Quintiles, Inc., Takeda Development Center Americas, Inc.
6/19/18 → 6/19/21
Project: Research project
-
APD334-005: An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI) & Baidoo, L. K. (Other)
PPD Investigator Services, LLC, Arena Pharmaceuticals, Inc.
1/12/18 → 1/12/21
Project: Research project
-
A Collaborative Study to Evaluate the Efficacy of Prospective Post-Induction Infliximab Dosing Based on Trough Levels at week 12 and 28 in Subjects with Crohn’s Disease (CD) and Ulcerative Colitis (UC)
Bellaguarda, E. A. L. (PD/PI)
Northwestern Memorial Hospital, Digestive Health Foundation
9/1/17 → 8/31/19
Project: Research project
-
Prot# PTG-100-02: A Phase 2B Randomized, Double-Blind, Placebo-Controlled, Parallel Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects with Moderate to Severe Active Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI)
Covance Inc., Protagonist Therapeutics, Inc.
7/12/17 → 7/12/20
Project: Research project
-
Prot# MLN0002-3026: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects with Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI)
Quintiles, Inc., Takeda Development Center Americas, Inc.
5/2/17 → 5/2/20
Project: Research project
-
SPARC-17-06-A: Collaborative Study to Evaluate the Role of Neutrophil FCγ Receptor I (CD64 Index as a New Biomarker for Mucoasl Healing (MH) and Histologic Remission (HR) in Inflammatory Bowel Disease (IBD) Patients
Bellaguarda, E. A. L. (PD/PI)
Strategic Pharma-Academic Research Consortium
1/1/17 → 1/31/20
Project: Research project